ORIC Pharmaceuticals Inc

NASDAQ:ORIC  
17.27
-0.44 (-2.48%)
Products, Other Pre-Announcement

Oric Pharmaceuticals Announces FDA Clearance Of Ind Application For Oric-533, A Highly Potent, Orally Bioavailable Small Molecule Cd73 Inhibitor

Published: 06/28/2021 12:47 GMT
ORIC Pharmaceuticals Inc (ORIC) - Oric Pharmaceuticals Announces FDA Clearance of Ind Application for Oric-533, a Highly Potent, Orally Bioavailable Small Molecule Cd73 Inhibitor.
Oric Pharmaceuticals Inc - Expects to Initiate Single Agent Clinical Trial in an Undisclosed Tumor Type in 2h21.
Oric Pharmaceuticals Inc - Oric-533 Ind Filing is First of Three Ind/cta Filings Expected in 2021.
Oric Pharmaceuticals Inc - Ind Filing for Oric-944 and Cta Filing for Oric-114 Expected in Second Half of Year.
Oric Pharmaceuticals- FDA Has Cleared Co's Ind for Oric-533 to Proceed Into a First-in-human Clinical Trial.